Goldman Believes Key Update On Exact Sciences Reimbursement 'Appears Imminent'

Goldman Sachs analyst Isaac Ro issued an after-hours note Tuesday commenting on intraday price action in EXACT Sciences Corporation EXAS shares.

With EXACT shares up more than 30 percent over the session, Ro noted "an updated USPSTF website which could have bearing on future reimbursement of Cologuard."

The analyst said, "We take no position on the Final Recommendation and potential financial impact to EXAS but note the timing comes sooner than expected. If Cologuard were included as a recommended screening method we would view the news as a positive for EXAS shares."

Ro maintained a Neutral rating on shares of EXACT Sciences.